Laser photocoagulation7, virectomy, intravitrials injections of anti-vascular endothelial growth factors (VEGF) and triamcinolone acetonide are different available options for DME.8-10 Intravitrial Triamcinolonacetonide (IVTA) 4mg is considered primary or adjuvant therapy but dose may ranges from 4-25 mg.11 IVTA is a promising treatment for DME12 but inexicably linked to elevation of intraocular pressure13, retinal detachment, glaucoma, ocular hypertone, intraocular hemorrhage endophthalmitis14 and Subtenon triamcinolone.15-17. The gene discussed is VEGFA; the disease is retinal detachment.